20% off ‘Generic Competition, 2009 to 2013: Impact of patent expiries on sales of major drugs’

Dec. 17, 2010 - PRLog -- According to the 142 page report, 2009–13 will see major companies facing very different degrees of exposure to the potential loss of revenue to generics. Eli Lilly, Pfizer, Bristol-Myers Squibb, Merck and Takeda all face the potential loss of over 40% of their revenues, while companies such as Roche, Abbott and Astellas face minimal exposure.Others face varying degrees of exposure – often around 20% – and for many companies the most critical years will be 2011 and/or 2012. Potentially the most seriously impacted, because of their over-reliance on a single product are Pfizer, for which Lipitor accounted for 25% of its 2007 revenues, and Bristol-Myers Squibb, for which Plavix accounted for 30% of its 2007 revenues.

2011 will be potentially a nadir for the innovative pharmaceutical industry, with four products with combined US sales of $16bn (in 2007) amongst those losing market exclusivity. In Europe 11 products, most notably Lipitor but also Actos and Zyprexa, will lose market exclusivity. In the US a total of 13 products will lose exclusivity. While Lipitor with 2007 sales of $7.2bn will be the most significant, several other blockbuster agents will also lose exclusivity: Plavix $4.1bn, Seroquel $2.9bn, Actos $2.3bn, Zyprexa $2.2bn and Levaquin $1.6bn.

2012 will see a large number of drugs lose patent protection – a total of 20 significant products in the US and 14 in Europe. The most significant developments in Europe will be the loss of exclusivity for the antihypertensives Atacand and Aprovel. In the US the 20 drugs losing exclusivity will include three with 2007 US sales in excess of $2bn: the antidepressant Lexapro, the anti-asthmatic agent Singulair and the antihypertensive Diovan.

2013 will see the loss of patent protection for 10 products in Europe and 9 in the US. In Europe the key developments will be the loss of exclusivity for Plavix and Seretide plus a number of antiviral agents. In the US the key developments will be the loss of exclusivity for Aciphex and for Cymbalta.

The discounted report “Generic Competition, 2009 to 2013: The impact of patent expiries on sales of major drugs” is available at a 10% off from Report Buyer at:
http://www.reportbuyer.com/pharma_healthcare/generic_drug...

Reportbuyer Product Code: URC00019

Report Buyer http://www.reportbuyer.com/pharma_healthcare/generic_drug... is the online store for global business information. The website now lists more than 150,000 company overviews, market research reports, industry studies and business books from over 300 specialist publishers. Thousands of professionals from across the world make ReportBuyer.com their first choice in their search for quality business insight.

# # #

Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare.